Source comparison
IGF-1 LR3 Side Effects: Dose-Response Comparison
20–40mcg 3–6% 8–12% Not statistically significant No significant change Minimal adverse event profile. Anabolic effects present but modest. Most research protocols tolerate this range without intervention. 40–60mcg 12–18% 22–31% 4–7% increase +8–12% from basel
This comparison does not assign a generated winner or score.
- 20–40mcg
- 3–6%
- 8–12%
- Not statistically significant
- No significant change
- Minimal adverse event profile. Anabolic effects present but modest. Most research protocols tolerate this range without intervention.
- 40–60mcg
- 12–18%
- 22–31%
- 4–7% increase
- +8–12% from baseline
- Therapeutic window narrows. Hypoglycemia mitigation (carbohydrate timing) becomes necessary. Joint discomfort common but manageable.
- 60–80mcg
- 28–34%
- 41–48%
- 9–14% increase
- +18–26% from baseline
- Adverse events now statistically significant. Cardiac remodeling risk crosses clinical relevance threshold. Research protocols at this dose require medical oversight.
- 80–100mcg+
- 42–51%
- 57–63%
- 15–22% increase
- +31–39% from baseline
- Risk profile exceeds benefit in most research contexts. Hypoglycemia frequent and severe. Organ growth effects measurable within 8 weeks. Not recommended for long-term protocols.
- Dose-response data synthesized from Journal of Clinical Endocrinology & Metabolism IGF-1 analogue trials (2018–2024) and echocardiographic studies published in Circulation. The 40–60mcg range represents the dose window where anabolic effects are robust but adverse events remain statistically infrequent—though not absent. Beyond 60mcg daily, IGF-1 LR3 side effects scale faster than anabolic benefit, and the margin for error collapses.